

Press release for immediate release

Genomtec begins pilot production of Genomtec®ID analyzers

Wroclaw, Poland - January 12, 2022. - Genomtec S.A. "GMT", a NewConnect-listed medtech company specializing in the development of advanced technology in the area of point-of-care (POCT) genetic diagnostics, has begun pilot production of analyzers for the first 15 Genomtec®ID devices. The analysers are being manufactured by the Genomtec team in the UK in close collaboration with the CDMO partner there. The start of production was made possible by the completion of the design and reliability testing of the analyzer components. The first 15 devices will be used in clinical comparative studies, the results of which will be used to register Genomtec®ID as an in-vitro diagnostic medical device under the IVD directive in the European Union in the first half of this year.

- I am proud that our team has successfully completed the design and testing and in such a small space have managed to include all the necessary components to perform genetic diagnosis of infections. The analyzer is a small and lightweight device measuring 16.5 cm by 11.5 cm and 11 cm high. It fits in the palm of your hand and makes it easy to carry wherever and whenever you want. This small size is achieved by our patented technique of non-contact photonic heating and by using the latest technology in electronics and mechanics. – said Miron Tokarki, CEO and co-founder of Genomtec.

Genomtec®ID, is a technology platform that will provide patients with ultra-fast mobile genetic diagnostics performed using SNAAT® technology. Genomtec®ID allows the diagnostic process to be performed at the point of care, without the need for complex and time-consuming handling in the laboratory by qualified personnel.. The first panel of Genomtec®ID will test for 5-pathogens of respiratory diseases, including Influenza, RSV, SARS-CoV-2 and two atypical pneumoniae bacterial infections. The Company plans to register the Genomtec®ID platform in the middle of this year.

#####

Additional information :

Genomtec S.A.

Magdalena Kicińska

+48 604 201 230

m.kicinska@genomtec.com

About Genomtec:

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the



proprietary, patent protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

Genomtec was founded in 2016. Genomtec SA is headquartered in Wrocław.

More information at: www.genomtec.com Genomtec została założona w 2016 r. Siedziba Spółki Genomtec SA znajduje się we Wrocławiu.

Więcej informacji: www.genomtec.com